Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
BRKR US Equity
BRUKER CORP
56.25USD▼ 4.40%
Healthcare
Medical Devices
96)Comparar97)Tesis →
Market Cap
$8.6B
Shares Outstanding
152M
P/FCF (TTM)
91.3×
EV/EBITDA
35.1×
Revenue (TTM)
$3.5B
Net Income (TTM)
−$71M
FCF (TTM)
$94M
— Annual —FY2025
Revenue
$3.4B
Gross Margin
45.9%
Operating Margin
2.0%
Net Margin
-0.3%
FCF Margin
1.3%
ROE
-0.3%
ROCE
1.4%
Net Debt/EBITDA
5.4×
Current Ratio
1.73
D/E Ratio
0.76
Dividend Yield
0.3%
FCF / Share
0.28
Book Value / Share
16.12
BRKR US Equity
56.25USD▼ 4.40%
Tesis →

BRUKER CORP (BRKR): análisis fundamental y valoración

BRUKER CORP cotiza a 56.25 USD y tiene una capitalización bursátil de $8.6B. En los últimos 12 meses ha facturado $3.5B con un margen de flujo de caja libre del 1.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaNasdaqPaísUnited StatesEmpleados11,085Beta1.22Web↗ www.bruker.com

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers …

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
197.9×
P/FCF (TTM)
91.3×
EV/EBITDA
35.1×
EV/Revenue
3.0×
P/Sales
2.5×
P/Book
3.5×
Rentabilidad (Último Anual)
Gross Margin
45.9%
Operating Margin
2.0%
Net Margin
-0.3%
FCF Margin
1.3%
ROE
-0.3%
ROCE
1.4%
ROA
-0.1%
Effective Tax Rate
—
Métricas TTM
Revenue TTM
$3.5B
Gross Profit TTM
$1.6B
Operating Income TTM
−$31M
Net Income TTM
−$71M
FCF TTM
$94M
EPS TTM
-0.7
Quarters Used
4
TTM Period
2025-09-30 → 2026-06-30
Solidez del Balance
Net Debt
$1.6B
Net Debt / EBITDA
5.4×
Debt / Equity
0.76
Current Ratio
1.73
Interest Coverage
75.8×
Working Capital
$933M
Book Value / Share
16.12
Net Debt / Share
10.31
Crecimiento (YoY)
Revenue YoY
+2.1%
Net Income YoY
-107.6%
FCF YoY
-68.2%
EPS Diluted YoY
-119.7%
Retorno al Accionista
Dividend Yield
0.3%
Payout Ratio
—
FCF / Share
0.28
CapEx % Revenue
2.6%
Rev / Employee
310,013
Próximos Eventos
Ex-Dividendo
2026-09-21
Pago Dividendo
2026-10-07
Historial EPS
Periodo2026-112026-082026-052026-02
Real—$0.49$0.31$0.59
Estimado$0.42$0.38$0.23$0.65
Sorpresa—+28.9%+34.8%-9.2%
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaBRKRMediana SectorΔ
Gross Margin45.9%57.0%-11.1%
Operating Margin2.0%-38.6%+40.6%
Net Margin-0.3%-33.6%+33.3%
FCF Margin1.3%-13.9%+15.1%
ROE-0.3%-40.4%+40.0%
ROA-0.1%-32.0%+31.9%
Current Ratio1.732.84-1.11
Debt / Equity0.760.28+0.48
Scoring Fundamental
Piotroski F-Score
4/ 9Débil
✗F1ROA positivo (rentabilidad activos)
✓F2Flujo caja operativo positivo
✗F3ROA mejora vs año anterior
✓F4Calidad de beneficios (OCF > ROA)
✓F5Apalancamiento baja
✓F6Liquidez mejora (current ratio)
✗F7Sin dilución accionarial
✗F8Margen bruto mejora
✗F9Rotación activos mejora
Altman Z-ScoreZona Gris
2.67
x1_working_capital0.149
x2_retained_earnings0.378
x3_ebit0.011
x4_market_equity2.297
x5_sales0.551
>2.99 segura · 1.81–2.99 gris · <1.81 riesgo
Capital Allocation
3/ 8Débil
✓FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✗DilucSin dilución significativa (< 2%/año en 3 años)
✓Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)
Histórico Piotroski F-Score
Histórico de Múltiplos